Suppression of malignant rhabdoid tumors through Chb‐M′‐mediated RUNX1 inhibition. Issue 2 (12th November 2020)

• Record Type: Journal Article
• Authors: Daifu, Tomoo; Mikami, Masamitsu; Hiramatsu, Hidefumi; Iwai, Atsushi; Umeda, Katsutsugu; Noura, Mina; Kubota, Hirohito; Masuda, Tatsuya; Furuichi, Kana; Takasaki, Saho; Noguchi, Yuki; Morita, Ken; Bando, Toshikazu; Hirata, Masahiro; Kataoka, Tatsuki R.; Nakahata, Tatsutoshi; Kuwahara, Yasumichi; Iehara, Tomoko; Hosoi, Hajime; Takita, Junko; Sugiyama, Hiroshi; Adachi, Souichi; Kamikubo, Yasuhiko
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-11-12
• Subjects: malignant rhabdoid tumor -- p53 -- polyamide -- RUNX1; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28789
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Malignant rhabdoid tumor (MRT) is a rare and highly aggressive pediatric malignancy primarily affecting infants and young children. Intensive multimodal therapies currently given to MRT patients are not sufficiently potent to control this highly malignant tumor. Therefore, additive or alternative therapy for these patients with a poor prognosis is necessary. We herein demonstrated that the inhibition of runt‐related transcription factor 1 (RUNX1) by novel alkylating conjugated pyrrole‐imidazole (PI) polyamides, which specifically recognize and bind to RUNX‐binding DNA sequences, was highly effective in the treatment of rhabdoid tumor cell lines in vitro as well as in an in vivo mouse model. Therefore, suppression of RUNX1 activity may be a novel strategy for MRT therapy.